Health Canada has published a report on its public consultation on building a national strategy to address access to drugs for rare diseases. This report follows the Government of Canada’s commitment to create a national strategy for drugs for rare diseases based on recommendations made by the Advisory Council on the Implementation of National Pharmacare.
The “What We Heard Report” is organized around four major themes that were identified in Health Canada’s discussion paper and addressed in the consultation feedback. Health Canada’s report observes, inter alia:
- Ensure consistent access. Provincial and territorial formularies can have different criteria